Biochem Pharma (BCHE) - 75% Discount - 500 Beiträge pro Seite
eröffnet am 08.06.00 21:17:50 von
neuester Beitrag 13.08.00 23:42:17 von
neuester Beitrag 13.08.00 23:42:17 von
Beiträge: 47
ID: 154.207
ID: 154.207
Aufrufe heute: 0
Gesamt: 928
Gesamt: 928
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 19:46 | 6955 | |
| vor 1 Stunde | 5647 | |
| vor 40 Minuten | 4931 | |
| heute 21:21 | 4540 | |
| vor 1 Stunde | 3184 | |
| heute 19:32 | 2325 | |
| heute 14:53 | 1982 | |
| vor 14 Minuten | 1832 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.182,00 | +0,59 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3575 | +0,27 | 60 | |||
| 5. | 4. | 168,52 | -0,98 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,8025 | +6,45 | 34 | |||
| 8. | Neu! | 11,828 | +13,73 | 31 |
Feedback
Habe heute ausnahmsweise die Hordenbach-Hotline angerufen.
Diess war früh am Morgen und somit noch das Thema von gestern „neuer Biotechknaller“.
Nachdem er noch über Rhein Biotech laberte, dass diese kurz vor dem Ausbruch stünden (womit klar sein dürfte warum gerade gestern der Ausbruch kam), kam er zum eigentlichen Knlaller, wobei er sich selbst noch das bisherige Nichtbeachten des Wertes vorwarf. Nach circa 2 Minuten nennt er endlich den Namen - Grund genug, um jetzt aufzulegen.
Der Anruf bei der Hotline hat bei DM 2,42 /Minute also rund DM 5,- gekostet, was 75% weniger ist als der Preis für eine Ausgabe des Biotechreports. Dieser ist ja, wie ich ja schon begründete, allerhöchstens dazu da, Namen von guten bislang unbeachteten Unternehmen zu nennen.
Kommen wir nun zum Wert: Biochem Pharmaceuticals (BCHE).
Dieser ist entgegen den Erwartungen von euch kein Smallcap, um dies mal vorwegzunehmen.
BCHE ist ein kanadisches Unternehmen. Hier ein übersichtliches Fact-Sheet im pdf.-Format http://www.biochempharma.com/PDF/Factsheet000508-a.PDF
BCHE ist grob unterteilt in 2 Bereichen tätig; Therapeutika und Impfstoffe.
Der noch kleinere Bereich Impfstoffe hat bislang ein marktreiges Produkt hervorgebracht: Fluviral, einen Impstoff gegen Grippe.
Ansonsten gibt´s hier nur vorklinische oder Phase I Präparate, also noch uninteresaantes.
In sich hat es aber der Therapeutika-Bereich, wo bereits 4 Produkte zur Marktreife entwickelt wurden:
Zeffix ist ein Präparat gegen chronische Hepatitis B, einer Art der Leberentzündung. Dieses ist bereits in 45 Ländern zugelassen, wobei weitere folgen werden. Von chronischer Hepatitis B Erkrankung sind weltweit 364 Mio Menschen betroffen!
Pacis ist ein Präparat gegen Blasenkrebs, dass vor kurzem erst zugelassen wurde und somit wahrscheinlich noch nichts zum Umsatz beiträgt.
Am wichtigsten für BCHE sind aber die HIV-Präparate. So unhuman dies auch klingen mag, aber dies ist ein WAchstumsmarkt (bitte keine Proteststürme, will hiermit nicht unmenschlich sein, sehe diesen SAtz rein betreibswirtschaftlich!,). Lt. Prospekt gab es 1998 bereits 33,6 Millionen AIDS-Infizierte weltweit, wobei allein 1999 5,6 Mio dazukamen ( +16,66%).
3TC (Epivir) ist lt. Firmenangaben das weltweit in über 100 Ländern meistverschriebe Präparat zur Behandlung des HI-Virus. Hierbei erhält BCHE Anteilszahlungen von Glaxo Wellcome, die damit 1999 weltweit 873 Mio $ umsetzen.Hierin sind aber auch die Umsätze con Combivir, einem Mischpräparat aus 3TC und Retrovir (Präparat von anderem Hersteller).
Desweitren gibt es hier noch, um diesen Bereich zuerst abzuschließen, ein Präparat, dass bereits Phase III komplettiert hat, aber noch nicht auf dem MArkt ist: Trizivir ist aber paradoxerweise nicht näher erläutert.
Zudem gibt es hier noch zwei vorklinische Präparate Präparate (-)dOTC und BCH-13520, die ähnlich wie 3TC sind.
Des letze Produkt, das sich auf dem MArkt befindet heißt Pacis und wird bei der Behandlung von Blasenkrebs eingesetzt. Dieses wurde auch erst vor kurzem zugelassen.
Ansonsten gibt’s es noch 2 weitere Phase II Präparate.
Zum einen Troxacitabine, das gegen verschiedene Krebsarten und Tumore eingesetzt wird.
Zum anderen mit BCH-13520 ein Präparat zur Schmerzkontrolle.
Unternehmensdaten:
Umsätze (in Mill CAN-$): 1996 89,74
1997 162,86
1998 224,97
1999 290,28
Ergenis je Aktie (in CAn-$): 1996 0,31
1997 0,74
1998 1,06
1999 1,42
2000e 1,43
2001e 1,56
Die letzten beiden Zahlen sind die in CAN-$ umgerechneten Konsensschätzungen von Yahoo!-Finance.
in US-$:
Marktkapitalisierung: 2,64 Mrd
KGV01e bei akt. Kurs von 241/4 $: 22,88
Was ist nun von diesem Unternehmen zu halten:
Die Nalysten bei Yahoo geben 7x Strong Buy, 3x Buy und 6x Hold, so dass unterm Strich ein Buy-Rating verbleibt.
Auffallend ist dabei die hohe Anzahl von sowohl strong buy als auch hold-ratings, was zeigt, dass die ANalysten vielleicht auch nicht so genau wissen, wie sie das Unternehmen bewerten sollen, weil sie so uneins sind.
Auffällig an der UNternehmensentwicklung ist der seit 1999 fast stagnierende Gewinn, was bei BCHE, da schon 5 Produkte auf dem MArkt sind, relevant ist.
Andererseits tragen aber noch nicht alle diese Produkte signifikant zum Umsatz bei bzw. der Umsatz wird durch Neuzulassungen in anderen Ländrn noch ausgeweitet werden.
Für Hordenbach jedenfalls könnte BCHE ein neuer Highflyer werden, was man bei Betrachtung der Produkte auch nachvollziehen kann.
Ich persönlich halte Hordenbach auf alle Fälle für fähig, vor allem , weil er die Werte, die empfiehlt, meist nicht selbst pushen kann, da dies US-Unternehmen sind.
Wie gesagt, BCHE ist kein small-cap, sondern ein reifes Biopharmazeutisches Unternehmen.
Diess war früh am Morgen und somit noch das Thema von gestern „neuer Biotechknaller“.
Nachdem er noch über Rhein Biotech laberte, dass diese kurz vor dem Ausbruch stünden (womit klar sein dürfte warum gerade gestern der Ausbruch kam), kam er zum eigentlichen Knlaller, wobei er sich selbst noch das bisherige Nichtbeachten des Wertes vorwarf. Nach circa 2 Minuten nennt er endlich den Namen - Grund genug, um jetzt aufzulegen.
Der Anruf bei der Hotline hat bei DM 2,42 /Minute also rund DM 5,- gekostet, was 75% weniger ist als der Preis für eine Ausgabe des Biotechreports. Dieser ist ja, wie ich ja schon begründete, allerhöchstens dazu da, Namen von guten bislang unbeachteten Unternehmen zu nennen.
Kommen wir nun zum Wert: Biochem Pharmaceuticals (BCHE).
Dieser ist entgegen den Erwartungen von euch kein Smallcap, um dies mal vorwegzunehmen.
BCHE ist ein kanadisches Unternehmen. Hier ein übersichtliches Fact-Sheet im pdf.-Format http://www.biochempharma.com/PDF/Factsheet000508-a.PDF
BCHE ist grob unterteilt in 2 Bereichen tätig; Therapeutika und Impfstoffe.
Der noch kleinere Bereich Impfstoffe hat bislang ein marktreiges Produkt hervorgebracht: Fluviral, einen Impstoff gegen Grippe.
Ansonsten gibt´s hier nur vorklinische oder Phase I Präparate, also noch uninteresaantes.
In sich hat es aber der Therapeutika-Bereich, wo bereits 4 Produkte zur Marktreife entwickelt wurden:
Zeffix ist ein Präparat gegen chronische Hepatitis B, einer Art der Leberentzündung. Dieses ist bereits in 45 Ländern zugelassen, wobei weitere folgen werden. Von chronischer Hepatitis B Erkrankung sind weltweit 364 Mio Menschen betroffen!
Pacis ist ein Präparat gegen Blasenkrebs, dass vor kurzem erst zugelassen wurde und somit wahrscheinlich noch nichts zum Umsatz beiträgt.
Am wichtigsten für BCHE sind aber die HIV-Präparate. So unhuman dies auch klingen mag, aber dies ist ein WAchstumsmarkt (bitte keine Proteststürme, will hiermit nicht unmenschlich sein, sehe diesen SAtz rein betreibswirtschaftlich!,). Lt. Prospekt gab es 1998 bereits 33,6 Millionen AIDS-Infizierte weltweit, wobei allein 1999 5,6 Mio dazukamen ( +16,66%).
3TC (Epivir) ist lt. Firmenangaben das weltweit in über 100 Ländern meistverschriebe Präparat zur Behandlung des HI-Virus. Hierbei erhält BCHE Anteilszahlungen von Glaxo Wellcome, die damit 1999 weltweit 873 Mio $ umsetzen.Hierin sind aber auch die Umsätze con Combivir, einem Mischpräparat aus 3TC und Retrovir (Präparat von anderem Hersteller).
Desweitren gibt es hier noch, um diesen Bereich zuerst abzuschließen, ein Präparat, dass bereits Phase III komplettiert hat, aber noch nicht auf dem MArkt ist: Trizivir ist aber paradoxerweise nicht näher erläutert.
Zudem gibt es hier noch zwei vorklinische Präparate Präparate (-)dOTC und BCH-13520, die ähnlich wie 3TC sind.
Des letze Produkt, das sich auf dem MArkt befindet heißt Pacis und wird bei der Behandlung von Blasenkrebs eingesetzt. Dieses wurde auch erst vor kurzem zugelassen.
Ansonsten gibt’s es noch 2 weitere Phase II Präparate.
Zum einen Troxacitabine, das gegen verschiedene Krebsarten und Tumore eingesetzt wird.
Zum anderen mit BCH-13520 ein Präparat zur Schmerzkontrolle.
Unternehmensdaten:
Umsätze (in Mill CAN-$): 1996 89,74
1997 162,86
1998 224,97
1999 290,28
Ergenis je Aktie (in CAn-$): 1996 0,31
1997 0,74
1998 1,06
1999 1,42
2000e 1,43
2001e 1,56
Die letzten beiden Zahlen sind die in CAN-$ umgerechneten Konsensschätzungen von Yahoo!-Finance.
in US-$:
Marktkapitalisierung: 2,64 Mrd
KGV01e bei akt. Kurs von 241/4 $: 22,88
Was ist nun von diesem Unternehmen zu halten:
Die Nalysten bei Yahoo geben 7x Strong Buy, 3x Buy und 6x Hold, so dass unterm Strich ein Buy-Rating verbleibt.
Auffallend ist dabei die hohe Anzahl von sowohl strong buy als auch hold-ratings, was zeigt, dass die ANalysten vielleicht auch nicht so genau wissen, wie sie das Unternehmen bewerten sollen, weil sie so uneins sind.
Auffällig an der UNternehmensentwicklung ist der seit 1999 fast stagnierende Gewinn, was bei BCHE, da schon 5 Produkte auf dem MArkt sind, relevant ist.
Andererseits tragen aber noch nicht alle diese Produkte signifikant zum Umsatz bei bzw. der Umsatz wird durch Neuzulassungen in anderen Ländrn noch ausgeweitet werden.
Für Hordenbach jedenfalls könnte BCHE ein neuer Highflyer werden, was man bei Betrachtung der Produkte auch nachvollziehen kann.
Ich persönlich halte Hordenbach auf alle Fälle für fähig, vor allem , weil er die Werte, die empfiehlt, meist nicht selbst pushen kann, da dies US-Unternehmen sind.
Wie gesagt, BCHE ist kein small-cap, sondern ein reifes Biopharmazeutisches Unternehmen.
Hat hier vielleicht einer die gesamte Hotline abgehört
Habe BCHE nur mla vorgestelt, da sie hierzulande unbekannt ist.
Mehr aber auch nicht.
Kaufen würde ich zur Zeit eher VRTX. Ist ja in aller Munde
Mehr aber auch nicht.
Kaufen würde ich zur Zeit eher VRTX. Ist ja in aller Munde
Gebe folgene Wette ab:
BCHE wird, falls sie sich nicht zu schlecht entwicklen, erst 1 oder 2 Mal auf der Hotline erwähnt
Dann folgt im Juli die Vorstellung im Biotech-Report (krieg ich dann wenigstens noch mit, (da letzte Ausgabe von meinem mittlerweile gekündigtem Probeabo).
Anschließend kommt dann Ende Juli auch mal ein Artikel im Aktionär, vielleicht im Rahmen der "traditionellen" Top-Aussichten-Titelstory, wenn die Kurse an ihrem Hoch angelangt sind.
Beispiel
1998 Internet-Werte wurden vorgestellt: @home, Egghead, Oz Email ...
1999 letzte Juli-Ausgabe: Jetzt optimaler Einstiegszeitpunkt, wenn nur die JAhreszeit nicht wäre
2000e Thema:"Die Biotech-Stars der nächsten Generation" u.a. BCHE
Geht meine Fantasie mal wieder mit mir durch?
Jedenfalls wird irgendwann einmal dieser Wert auch Einzug in "Der Aktionär" finden. Dann kann dieser Thread ja weitergeführt werden.
BCHE wird, falls sie sich nicht zu schlecht entwicklen, erst 1 oder 2 Mal auf der Hotline erwähnt
Dann folgt im Juli die Vorstellung im Biotech-Report (krieg ich dann wenigstens noch mit, (da letzte Ausgabe von meinem mittlerweile gekündigtem Probeabo).
Anschließend kommt dann Ende Juli auch mal ein Artikel im Aktionär, vielleicht im Rahmen der "traditionellen" Top-Aussichten-Titelstory, wenn die Kurse an ihrem Hoch angelangt sind.
Beispiel
1998 Internet-Werte wurden vorgestellt: @home, Egghead, Oz Email ...
1999 letzte Juli-Ausgabe: Jetzt optimaler Einstiegszeitpunkt, wenn nur die JAhreszeit nicht wäre
2000e Thema:"Die Biotech-Stars der nächsten Generation" u.a. BCHE
Geht meine Fantasie mal wieder mit mir durch?
Jedenfalls wird irgendwann einmal dieser Wert auch Einzug in "Der Aktionär" finden. Dann kann dieser Thread ja weitergeführt werden.
Aus der Piper Jefray Konferenz:
News June 16, 09:37 Eastern Time
BioChem Pharma (Nasdaq: BCHE) is on the rebound, according to Augustine. "Zeffix
sales have begun to accelerate and BioChem Pharma, an unbelievably cheap stock,
might actually be a stock in rebound this year as Zeffix sales accelerate and
they get an interesting cancer drug, troxacitabine, through Phase II studies. We
project a 31% five-year earnings growth."
News June 16, 09:37 Eastern Time
BioChem Pharma (Nasdaq: BCHE) is on the rebound, according to Augustine. "Zeffix
sales have begun to accelerate and BioChem Pharma, an unbelievably cheap stock,
might actually be a stock in rebound this year as Zeffix sales accelerate and
they get an interesting cancer drug, troxacitabine, through Phase II studies. We
project a 31% five-year earnings growth."
Trading Spotlight
Wieso gibt es hier keine INtersssierten?
Hier gibt´s doch genug Förtsch-Freunde.
Hordenbach arbeitet für ihn!!!
ach ja, was Olaf H. sagte, bevor er den Namen sagte: "ein in Deutschland völlig unbekannter Wert... mit dem Sie in den nächsten Wochen sehr viel Geld verdienen können.
Hier gibt´s doch genug Förtsch-Freunde.
Hordenbach arbeitet für ihn!!!
ach ja, was Olaf H. sagte, bevor er den Namen sagte: "ein in Deutschland völlig unbekannter Wert... mit dem Sie in den nächsten Wochen sehr viel Geld verdienen können.
BCHE leidete in den letzten Monaten an schleppenden Produktverkäufen, allerdings wird jetzt eine Beschleunigung dieser Verkäufe erwartet. Daher rührt letztlich die Kursfantasie.
von 
Great potential...
If Zeffix sales take off, so will BCHE, I think.
Troxacitabine moving further along the pipeline should be a help too.
One of the "big chiefs" said that BCHE was cheap right now - it was at 22 USD - at the annual shareholders meeting, and that IF it was going to be a take-over target, it sure wasn`t going to be a friendly take-over.
They`re also very confident about the future.
With a low P/E when looking at the sector average and good potential for Zeffix, AND products in the pipeline, this is one stock to have...
Also, they know that downstream selling is more profitable, and they`re trying to head that way. Financial strength is good, it has better ratio`s than the sector, and is looking for take-overs.
Vaccine research is supported by Canadian government.
If nobody likes the stock, than I think that THAT`s the time to step in , hold on to it, and make easy money - for those who`ve had it for a while... hang on, you`ve got a great stock in your portfolio ! It will take off one day... maybe not tomorrow, but it will.
also auf deutsch, man braucht Zeit, aber die solte man bei Biotechs allgemein mitbringen!
Great potential...
If Zeffix sales take off, so will BCHE, I think.
Troxacitabine moving further along the pipeline should be a help too.
One of the "big chiefs" said that BCHE was cheap right now - it was at 22 USD - at the annual shareholders meeting, and that IF it was going to be a take-over target, it sure wasn`t going to be a friendly take-over.
They`re also very confident about the future.
With a low P/E when looking at the sector average and good potential for Zeffix, AND products in the pipeline, this is one stock to have...
Also, they know that downstream selling is more profitable, and they`re trying to head that way. Financial strength is good, it has better ratio`s than the sector, and is looking for take-overs.
Vaccine research is supported by Canadian government.
If nobody likes the stock, than I think that THAT`s the time to step in , hold on to it, and make easy money - for those who`ve had it for a while... hang on, you`ve got a great stock in your portfolio ! It will take off one day... maybe not tomorrow, but it will.
also auf deutsch, man braucht Zeit, aber die solte man bei Biotechs allgemein mitbringen!
Biochem Pharma auf einer Stufe mit den Großen:
First of all, there`s a wide variety of biotechnology companies out there. Some of them are already making rules in the industry and are raking in huge profits from products already on the market. Others have promising research pipelines and are close to breaking through with a new blockbuster drug that will propel them to profitability. Still others have promising technology but are still in the early stages of development. To simplify matters, I suggest that investors divide biotech companies into three groups: a top tier, which represents the established, large-cap biotech companies; a second tier, which includes companies that are close to being profitable; and a third tier, which includes everybody else.
The top tier consists of companies that already have one or more successful products on the market and enjoy minimum annual revenues of $500 million. Here are some of the companies in this tier: Amgen (Nasdaq: AMGN) , Biogen (Nasdaq: BGEN) , Chiron (Nasdaq: CHIR) , Genentech (NYSE: DNA) , Genzyme (Nasdaq: GENZ) , Immunex (Nasdaq: IMNX) , Medimmune (Nasdaq: MEDI) , Biochem Pharma (Nasdaq: BCHE) , and PE Biosystems (NYSE: PEB) .
First of all, there`s a wide variety of biotechnology companies out there. Some of them are already making rules in the industry and are raking in huge profits from products already on the market. Others have promising research pipelines and are close to breaking through with a new blockbuster drug that will propel them to profitability. Still others have promising technology but are still in the early stages of development. To simplify matters, I suggest that investors divide biotech companies into three groups: a top tier, which represents the established, large-cap biotech companies; a second tier, which includes companies that are close to being profitable; and a third tier, which includes everybody else.
The top tier consists of companies that already have one or more successful products on the market and enjoy minimum annual revenues of $500 million. Here are some of the companies in this tier: Amgen (Nasdaq: AMGN) , Biogen (Nasdaq: BGEN) , Chiron (Nasdaq: CHIR) , Genentech (NYSE: DNA) , Genzyme (Nasdaq: GENZ) , Immunex (Nasdaq: IMNX) , Medimmune (Nasdaq: MEDI) , Biochem Pharma (Nasdaq: BCHE) , and PE Biosystems (NYSE: PEB) .
Wednesday May 31, 10:11 am Eastern Time
worldlyinvestor.com Sector of the Day
Biotech Could Bring Home the Canadian Bacon
By William L. Valentine, Columnist
BioChem Pharma, known for discovering a key ingredient for the `HIV cocktail,` is looking cheap.
If the term ``cheap biotech stock`` strikes you as an oxymoron, let me introduce you to BioChem Pharma (Nasdaq:BCHE - news), a Canadian biopharmaceutical company that`s a give-away at these valuations. BioChem, best known for discovering 3TC, the world`s leading anti-HIV drug, is hitching its wagon to three rising stars: anti-infective, anti-cancer and vaccine medicines.
Laval, Quebec-based BioChem is an international biopharmaceutical company focused on the research, development and commercialization of medical products for the prevention and treatment of human diseases. BioChem relies heavily on marketing partnerships, most notably with Glaxo Wellcome (NYSE:GLX - news), for the distribution of its products. Thus, its major revenue source is royalties, as opposed to outright sales.
Recognizable competitors include Amgen (Nasdaq:AMGN - news), Genentech (NYSE
NA - news), Immunex (Nasdaq:IMNX - news), Medimmune (Nasdaq:MEDI - news), Biogen (Nasdaq:BGEN - news) and Chiron (Nasdaq:CHIR - news).
Mixing Cocktails
BioChem is most known for its anti-infective therapies. Its late founder Dr. Bernard Belleau discovered 3TC -- a compound known clinically as lamivudine, which is the world`s leading anti-HIV treatment -- now commonly used as part of the ``AIDS cocktail.`` 3TC, also marketed as Epivir or Combivir, is distributed by Glaxo worldwide, except in Canada where BioChem sells it directly.
The drug is currently being used by 80% of HIV patients on therapy and should reach $1 billion in sales in 2000. The annual growth for the drug in this market is expected to be around 8% and BioChem`s royalties tend to run in the range of 12% to 15% of sales. While 3TC is the current tail that wags the revenue dog of this company, the most exciting prospect for the company lies in a different use of the same compound, lamivudine.
Under the brand names Zeffix, Epivir-HBV, and Heptovir, lamivudine is being used to treat Hepatitis B, the chronic liver disease that`s far more reaching than AIDS or HIV. Hepatitis B is the ninth most common cause of death in the world, responsible for two million fatalities each year, and there are nearly 400 million carriers of the virus worldwide.
Hepatitis B Treatment
Zeffix is the first, and only, oral treatment for Hepatitis B, and is two years ahead of any competition in this market. In the coming years, this will easily top C$1 billion in sales. Of that, nearly half is expected to come from China, where Hepatitis B is an epidemic. Zeffix received approval for distribution from Chinese health authorities in January of last year, and BioChem and Glaxo locked up an exclusive manufacturing arrangement for eight years in the country. BioChem`s revenue from Zeffix should more than double in each of the next several years.
In the anti-cancer arena, BioChem manufactures PACIS, a treatment for bladder cancer. PACIS is an antineoplastic agent in the treatment of superficial cancers and acts through the promotion of local inflammatory reactions of the urinary bladder. It will be distributed in the US by UroCor (Nasdaq:UCOR - news), an Oklahoma-based company with a focus on urological disorders.
The company recently began Phase II trials of troxacitabine for use in the treatment of a variety of solid tumors and in leukemia. In the vaccine area, most remarkably, is Fluviral, the only Canadian-made flu vaccine required for annual vaccination programs. It has also been working on protections against meningitis and pneumonia. Its efforts in vaccine medicine was recently bolstered by the announcement of a joint effort with the Canadian government`s Technology Partnerships Canada that includes an infusion of C$80 million from the government over six years.
Pegged as a Cheap Stock
Overall, the company is in great financial shape. Revenues grew by 30% last year to C$290 million, earnings grew by the same amount on a 51% net margin, and the company`s long-term-debt-to-assets ratio is 20%. This company is firing on all three of its cylinders, critical to a thriving biotech. BioChem`s got established and growing revenue, a strong pipeline and a strong balance sheet.
Amazingly, it trades at a fraction of the valuations of its peers, many of whom can`t claim the three aforementioned characteristics. BioChem stock trades at 21 times next year`s expected earnings, and as a conservative, long-term projected earnings growth rate of 26%That means its P/E to Growth (PEG) is an unbelievably low 0.8. When you compare that with richly priced Amgen`s PEG of 3.3 or Genentech`s 3.4, you`ll see what I mean by cheap biotech stock..
.[/b]
Editor`s Note: This story was changed from the original copy to fix a figure incorrectly labeled as Canadian dollars, a misstated royalties percentage and to specify the time frame in which the company will receive an infusion from the government.
William L. Valentine, CFA, is president of <a href=``http://www.valentineventures.com/``>Valentine Ventures LLC,</a> an investment manager of global stocks for individual investors. His weekly column, ``ADR of the Week,`` focuses on one foreign stock that trades in the US as an American Depositary Receipt (ADR). At the time of publication, the author owned shares of BioChem Pharma stock in client accounts.
worldlyinvestor.com Sector of the Day
Biotech Could Bring Home the Canadian Bacon
By William L. Valentine, Columnist
BioChem Pharma, known for discovering a key ingredient for the `HIV cocktail,` is looking cheap.
If the term ``cheap biotech stock`` strikes you as an oxymoron, let me introduce you to BioChem Pharma (Nasdaq:BCHE - news), a Canadian biopharmaceutical company that`s a give-away at these valuations. BioChem, best known for discovering 3TC, the world`s leading anti-HIV drug, is hitching its wagon to three rising stars: anti-infective, anti-cancer and vaccine medicines.
Laval, Quebec-based BioChem is an international biopharmaceutical company focused on the research, development and commercialization of medical products for the prevention and treatment of human diseases. BioChem relies heavily on marketing partnerships, most notably with Glaxo Wellcome (NYSE:GLX - news), for the distribution of its products. Thus, its major revenue source is royalties, as opposed to outright sales.
Recognizable competitors include Amgen (Nasdaq:AMGN - news), Genentech (NYSE
NA - news), Immunex (Nasdaq:IMNX - news), Medimmune (Nasdaq:MEDI - news), Biogen (Nasdaq:BGEN - news) and Chiron (Nasdaq:CHIR - news).Mixing Cocktails
BioChem is most known for its anti-infective therapies. Its late founder Dr. Bernard Belleau discovered 3TC -- a compound known clinically as lamivudine, which is the world`s leading anti-HIV treatment -- now commonly used as part of the ``AIDS cocktail.`` 3TC, also marketed as Epivir or Combivir, is distributed by Glaxo worldwide, except in Canada where BioChem sells it directly.
The drug is currently being used by 80% of HIV patients on therapy and should reach $1 billion in sales in 2000. The annual growth for the drug in this market is expected to be around 8% and BioChem`s royalties tend to run in the range of 12% to 15% of sales. While 3TC is the current tail that wags the revenue dog of this company, the most exciting prospect for the company lies in a different use of the same compound, lamivudine.
Under the brand names Zeffix, Epivir-HBV, and Heptovir, lamivudine is being used to treat Hepatitis B, the chronic liver disease that`s far more reaching than AIDS or HIV. Hepatitis B is the ninth most common cause of death in the world, responsible for two million fatalities each year, and there are nearly 400 million carriers of the virus worldwide.
Hepatitis B Treatment
Zeffix is the first, and only, oral treatment for Hepatitis B, and is two years ahead of any competition in this market. In the coming years, this will easily top C$1 billion in sales. Of that, nearly half is expected to come from China, where Hepatitis B is an epidemic. Zeffix received approval for distribution from Chinese health authorities in January of last year, and BioChem and Glaxo locked up an exclusive manufacturing arrangement for eight years in the country. BioChem`s revenue from Zeffix should more than double in each of the next several years.
In the anti-cancer arena, BioChem manufactures PACIS, a treatment for bladder cancer. PACIS is an antineoplastic agent in the treatment of superficial cancers and acts through the promotion of local inflammatory reactions of the urinary bladder. It will be distributed in the US by UroCor (Nasdaq:UCOR - news), an Oklahoma-based company with a focus on urological disorders.
The company recently began Phase II trials of troxacitabine for use in the treatment of a variety of solid tumors and in leukemia. In the vaccine area, most remarkably, is Fluviral, the only Canadian-made flu vaccine required for annual vaccination programs. It has also been working on protections against meningitis and pneumonia. Its efforts in vaccine medicine was recently bolstered by the announcement of a joint effort with the Canadian government`s Technology Partnerships Canada that includes an infusion of C$80 million from the government over six years.
Pegged as a Cheap Stock
Overall, the company is in great financial shape. Revenues grew by 30% last year to C$290 million, earnings grew by the same amount on a 51% net margin, and the company`s long-term-debt-to-assets ratio is 20%. This company is firing on all three of its cylinders, critical to a thriving biotech. BioChem`s got established and growing revenue, a strong pipeline and a strong balance sheet.
Amazingly, it trades at a fraction of the valuations of its peers, many of whom can`t claim the three aforementioned characteristics. BioChem stock trades at 21 times next year`s expected earnings, and as a conservative, long-term projected earnings growth rate of 26%That means its P/E to Growth (PEG) is an unbelievably low 0.8. When you compare that with richly priced Amgen`s PEG of 3.3 or Genentech`s 3.4, you`ll see what I mean by cheap biotech stock..
.[/b]
Editor`s Note: This story was changed from the original copy to fix a figure incorrectly labeled as Canadian dollars, a misstated royalties percentage and to specify the time frame in which the company will receive an infusion from the government.
William L. Valentine, CFA, is president of <a href=``http://www.valentineventures.com/``>Valentine Ventures LLC,</a> an investment manager of global stocks for individual investors. His weekly column, ``ADR of the Week,`` focuses on one foreign stock that trades in the US as an American Depositary Receipt (ADR). At the time of publication, the author owned shares of BioChem Pharma stock in client accounts.
um´s noch mal deutlich herauzustellen. Ich will hier BCHE nicht sinnlos pushen - ganz im Gegenteil!
Ich will euch nur mal aufzeigen, dass BCHE ein spitzenmäßiges langristiges Investment darstellt.
vielleicht sind einige hieretwas misstrauisch, weil sie den Namen noch nie gehört haben. Aber BCHE ist eben ein in Deutschland unbekannter Wert, ein Substanz-Wert!
Bin mal gespannt, wann Hordenbach sie das nächste Mal auf seiner Hotline erwähnt.
Spätestens wenn sie im Biotech Report ist, was in absehbarer Zeit wohl passieren dürfte, werden einige hier ganz scharf auf Biochem sein!
Ich will euch nur mal aufzeigen, dass BCHE ein spitzenmäßiges langristiges Investment darstellt.
vielleicht sind einige hieretwas misstrauisch, weil sie den Namen noch nie gehört haben. Aber BCHE ist eben ein in Deutschland unbekannter Wert, ein Substanz-Wert!
Bin mal gespannt, wann Hordenbach sie das nächste Mal auf seiner Hotline erwähnt.
Spätestens wenn sie im Biotech Report ist, was in absehbarer Zeit wohl passieren dürfte, werden einige hier ganz scharf auf Biochem sein!
Hi IWA Japan,
danke für die Infos, jedoch ist Deine letzte Meldung ein wenig alt.
thanks
MSolver
danke für die Infos, jedoch ist Deine letzte Meldung ein wenig alt.
thanks
MSolver
Wieso? 2 Wochen, zudem ist sie immer noch gültig, da grundliegende INformation
Biochem ist auch im Portfolio von BB Biotech !
Monday June 19, 11:04 am Eastern Time
Company Press Release
SOURCE: BioChem Pharma Inc.
Biochem Pharma Announces Development Collaboration and Licensing Agreement With Cytovax Biotechnologies@
LAVAL, Quebec, June 19 /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; TSE: BCH - news) announced the signing of a development and license agreement with Cytovax Biotechnologies Inc. initially to further develop a vaccine, currently in late-stage preclinical development, to prevent infections caused by Pseudomonas aeruginosa. A prophylactic vaccine would represent a significant benefit taking into consideration the increasing resistance of P. aeruginosa to treatment by antibiotics.
Based on Cytovax`s proprietary Anti-Adhesin Platform Technology (AAPT), this collaboration also includes a monoclonal antibody that could be used both as a preventive or a therapeutic agent.
P. aeruginosa is prevalent among hospital-acquired infections (nosocomial infections) and is the most common cause of hospital-acquired pneumonia. According to the Centers for Disease Control and Prevention, nosocomial infections affect approximately two million patients annually in the U.S., of which 12% are attributed to P. aeruginosa. Groups at high risk for infection by P. aeruginosa include cystic fibrosis patients, intubated patients, patients in intensive care units and burn victims. Mortality is high in these patients because P. aeruginosa colonizes rapidly with some strains being resistant to widely used antibiotics. By age 30, 80% of cystic fibrosis patients are colonized with P. aeruginosa and are subject to a 50% mortality rate within a decade.
``This collaboration with BioChem Pharma holds tremendous opportunity for Cytovax, as P. aeruginosa infection currently lacks satisfactory treatment and has a significant global market opportunity,` said Bin Huang, Ph.D., President and CEO of Cytovax. `Today`s agreement provides for the development of this vaccine and the extension of our AAPT technology platform to other infectious diseases such as Staphylococcus aureus, among others.``
``BioChem is very pleased to be partnering with Cytovax,`` said Mr. Jacques Lapointe, President and COO of BioChem. `Combining Cytovax`s proprietary platform technology and BioChem`s vaccine expertise creates exciting potential for the development of agents against this infection of increasing concern in hospitals. The at-risk population is very broad. The potential users of such a vaccine or monoclonal antibody could include all hospitalized patients. As an indication, an estimated 27 million surgical procedures are performed in hospitals each year in the U.S. alone,` he added.
BioChem will commit research funding and expertise to the alliance and will also purchase an equity stake in Cytovax. Further, Cytovax will receive development milestone payments and royalties on sales of products from this collaboration. BioChem receives the worldwide rights to develop, manufacture and market the products. Initial development will be conducted at Cytovax`s research and development facilities in Edmonton, Alberta, under the guidance of BioChem, while the final development program will be done by BioChem.
Cytovax is a Canadian biotechnology company that is focused on the development and commercialization of vaccines and therapeutic products for the prevention and treatment of infectious diseases. Cytovax is located in Edmonton, Alberta.
BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human diseases with a focus in the anti-infective and anticancer areas.
BioChem Pharma news releases and other company information can be found on the World Wide Web at www.biochempharma.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995, each of which involves risks and uncertainties that may affect the Company`s business and projects. Such forward-looking statements include, without limitation, the successful development and their marketing thereafter of a vaccine against infections caused by Pneudomonas aeruginosa and of a monoclonal antibody to be used as a preventive or therapeutic agent, the research funding and the equity investment in Cytovax, and the payment to Cytovax of milestone payments and royalties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of the preclinical development programs and of the clinical studies, obtaining the required approvals by regulatory authorities, the ability of BioChem to successfully introduce to the market the developed products and to capture the market or a portion thereof. Investors should consult the Company`s ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.
SOURCE: BioChem Pharma Inc.
Company Press Release
SOURCE: BioChem Pharma Inc.
Biochem Pharma Announces Development Collaboration and Licensing Agreement With Cytovax Biotechnologies@
LAVAL, Quebec, June 19 /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; TSE: BCH - news) announced the signing of a development and license agreement with Cytovax Biotechnologies Inc. initially to further develop a vaccine, currently in late-stage preclinical development, to prevent infections caused by Pseudomonas aeruginosa. A prophylactic vaccine would represent a significant benefit taking into consideration the increasing resistance of P. aeruginosa to treatment by antibiotics.
Based on Cytovax`s proprietary Anti-Adhesin Platform Technology (AAPT), this collaboration also includes a monoclonal antibody that could be used both as a preventive or a therapeutic agent.
P. aeruginosa is prevalent among hospital-acquired infections (nosocomial infections) and is the most common cause of hospital-acquired pneumonia. According to the Centers for Disease Control and Prevention, nosocomial infections affect approximately two million patients annually in the U.S., of which 12% are attributed to P. aeruginosa. Groups at high risk for infection by P. aeruginosa include cystic fibrosis patients, intubated patients, patients in intensive care units and burn victims. Mortality is high in these patients because P. aeruginosa colonizes rapidly with some strains being resistant to widely used antibiotics. By age 30, 80% of cystic fibrosis patients are colonized with P. aeruginosa and are subject to a 50% mortality rate within a decade.
``This collaboration with BioChem Pharma holds tremendous opportunity for Cytovax, as P. aeruginosa infection currently lacks satisfactory treatment and has a significant global market opportunity,` said Bin Huang, Ph.D., President and CEO of Cytovax. `Today`s agreement provides for the development of this vaccine and the extension of our AAPT technology platform to other infectious diseases such as Staphylococcus aureus, among others.``
``BioChem is very pleased to be partnering with Cytovax,`` said Mr. Jacques Lapointe, President and COO of BioChem. `Combining Cytovax`s proprietary platform technology and BioChem`s vaccine expertise creates exciting potential for the development of agents against this infection of increasing concern in hospitals. The at-risk population is very broad. The potential users of such a vaccine or monoclonal antibody could include all hospitalized patients. As an indication, an estimated 27 million surgical procedures are performed in hospitals each year in the U.S. alone,` he added.
BioChem will commit research funding and expertise to the alliance and will also purchase an equity stake in Cytovax. Further, Cytovax will receive development milestone payments and royalties on sales of products from this collaboration. BioChem receives the worldwide rights to develop, manufacture and market the products. Initial development will be conducted at Cytovax`s research and development facilities in Edmonton, Alberta, under the guidance of BioChem, while the final development program will be done by BioChem.
Cytovax is a Canadian biotechnology company that is focused on the development and commercialization of vaccines and therapeutic products for the prevention and treatment of infectious diseases. Cytovax is located in Edmonton, Alberta.
BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human diseases with a focus in the anti-infective and anticancer areas.
BioChem Pharma news releases and other company information can be found on the World Wide Web at www.biochempharma.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995, each of which involves risks and uncertainties that may affect the Company`s business and projects. Such forward-looking statements include, without limitation, the successful development and their marketing thereafter of a vaccine against infections caused by Pneudomonas aeruginosa and of a monoclonal antibody to be used as a preventive or therapeutic agent, the research funding and the equity investment in Cytovax, and the payment to Cytovax of milestone payments and royalties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of the preclinical development programs and of the clinical studies, obtaining the required approvals by regulatory authorities, the ability of BioChem to successfully introduce to the market the developed products and to capture the market or a portion thereof. Investors should consult the Company`s ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.
SOURCE: BioChem Pharma Inc.
BCHE vor Ausbruch? Mit 25 1/4 $ heute ist fast exakt das letzte lokale Hoch der Seitwärtsbewegung erreicht worden. Jetzt fehlt nur noch der Ausbruch!
Hier noch ein RB-Nachschlag:
Worldlyinvestor.com Stock Pick
Biochem Pharma was maintained "accumulate" by analyst Andre Uddin at Research Capital Corp. The 12-month target price is $41 per share.
Worldlyinvestor.com Stock Pick
Biochem Pharma was maintained "accumulate" by analyst Andre Uddin at Research Capital Corp. The 12-month target price is $41 per share.
For whatever reason, we are moving up here. I recently bought some calls based on the bullish chart. Volume is rising, we are above the 50 and 200 MA, and probably most importantly, we are still near the botttom of the large 5 year trading channel. One other interesting note. I notice that we are trading more shares on the Nasdaq now instead of the Toronto excahnge. This has not historically been the case, check teh quote/charts (BCH.TO is the Yhoo symbol for the Canuck stock) I`m not even sure what it means but it would a ppear there is more interest coming form the U.S. now.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
sieht doch gut aus, GD100 und 200 wurden erobert!
Hi IWA,
guten Morgen!
In den letzten Tagen beobachte ich ein zeitliches nach-und-nach Anspringen verschiedener Biotechs. Wenn ich deine Postings richtig verstehe, könnte es sein, dass der Index zunächst Halt macht bei 1250, aber es durchaus möglich ist, dass trotzdem einige Biotechs der zweiten oder dritten Reihe noch deutlich zweistellige Steigerungen vollziehen.
Folgende Aktien habe ich im Auge, von denen ich noch glaube, dass es zu Steigerungen kommen kann: TLRK, BCHE, AVAN, Amylin.Leider ohne fundamentals.
Hast du eine Erklärung, warum Genzyme die 60 nicht schafft?
MFG
bandolin
guten Morgen!
In den letzten Tagen beobachte ich ein zeitliches nach-und-nach Anspringen verschiedener Biotechs. Wenn ich deine Postings richtig verstehe, könnte es sein, dass der Index zunächst Halt macht bei 1250, aber es durchaus möglich ist, dass trotzdem einige Biotechs der zweiten oder dritten Reihe noch deutlich zweistellige Steigerungen vollziehen.
Folgende Aktien habe ich im Auge, von denen ich noch glaube, dass es zu Steigerungen kommen kann: TLRK, BCHE, AVAN, Amylin.Leider ohne fundamentals.
Hast du eine Erklärung, warum Genzyme die 60 nicht schafft?
MFG
bandolin
zum MArktprodukt Pacis aus Siliconinvestor:
UroCor Gets Orders For Drug To Fight Bladder Cancer
Dow Jones Newswires
OKLAHOMA CITY -- UroCor Inc. (UCOR) received its first orders for PACIS BCG, a drug made by BioChem Pharma Inc. (BCHE) for the treatment of bladder cancer.
In a press release Tuesday, UroCor said the recommended dosage for the drug, which physicians administer, is one dose per week for six weeks.
The Food and Drug Administration approved PACIS in February.
Jim
UroCor Gets Orders For Drug To Fight Bladder Cancer
Dow Jones Newswires
OKLAHOMA CITY -- UroCor Inc. (UCOR) received its first orders for PACIS BCG, a drug made by BioChem Pharma Inc. (BCHE) for the treatment of bladder cancer.
In a press release Tuesday, UroCor said the recommended dosage for the drug, which physicians administer, is one dose per week for six weeks.
The Food and Drug Administration approved PACIS in February.
Jim
eine Frage zu BCHe: Wie bist du auf sie gestoßen?
wg Genz: würde mich da nicht verücktmachen, 60$ ist bei denen eine wichtige Chartmarke!
noch die letzten Quartalsergebnisse als Ergänzung:
Biochem Pharma Beats Estimates
Tell us what you think in BCHE`s Board
http://www.individualinvestor.com
Senior Analyst: Eric Singer (5/1/00)
Late last week, Biochem Pharma (NASDAQ:BCHE - Quotes, News, Boards) released financial
results for its first quarter of fiscal 2000. Earnings per share of $0.28 per share were $0.06
ahead of consensus forecasts. Driving upside was $7.2 million in realized investment gains.
Sales of Biochem`s two key out-licensed products, Zeffix and 3TC posted strong results for the
quarter, with Zeffix sales of $20 million and 3TC sales of $200 million. Both Zeffix and 3TC
have demonstrated strong clinical utility and are prescribed to treat chronic hepatitis B and HIV,
respectively.
While worldwide sales of 3TC in U.S. dollars increased by only 3% on a year-over-year basis,
sales at constant exchange rates actually increased by 8% when compared to the same
period last year. Sales growth was strong in key geographies, including 10% growth in the
U.S. market, 9% growth in Western Europe and 4% in Canada. In other geographies, sales
decreased by 13%. Part of the decrease in other geographies may be related to stocking and
inventory issues with partner Glaxo Wellcome (NYSE:GLX - Quotes, News, Boards).
Zeffix sales surged to $20 million in the quarter, from $13.3 million just three months earlier.
Asian sales were especially strong. Further country approvals as well as reimbursement
should continue to fuel higher sales levels of Zeffix in future quarters.
Biochem achieved several key milestones in the first quarter that should drive shareholder
value over the course of this year. On March 15th, the company completed the divestiture of its
diagnostic business, a move that will enable it to focus resources on drug development
programs. Additionally, the company announced plans to partner with Technology
Partnerships Canada, a federal government agency, to develop protein vaccine technology.
The agreement provides for guaranteed funding to Biochem. Additionally, Biochem make
clinical progress on troxacitabine, an anti-cancer compound that the company is developing.
Biochem con
Biochem Pharma Beats Estimates
Tell us what you think in BCHE`s Board
http://www.individualinvestor.com
Senior Analyst: Eric Singer (5/1/00)
Late last week, Biochem Pharma (NASDAQ:BCHE - Quotes, News, Boards) released financial
results for its first quarter of fiscal 2000. Earnings per share of $0.28 per share were $0.06
ahead of consensus forecasts. Driving upside was $7.2 million in realized investment gains.
Sales of Biochem`s two key out-licensed products, Zeffix and 3TC posted strong results for the
quarter, with Zeffix sales of $20 million and 3TC sales of $200 million. Both Zeffix and 3TC
have demonstrated strong clinical utility and are prescribed to treat chronic hepatitis B and HIV,
respectively.
While worldwide sales of 3TC in U.S. dollars increased by only 3% on a year-over-year basis,
sales at constant exchange rates actually increased by 8% when compared to the same
period last year. Sales growth was strong in key geographies, including 10% growth in the
U.S. market, 9% growth in Western Europe and 4% in Canada. In other geographies, sales
decreased by 13%. Part of the decrease in other geographies may be related to stocking and
inventory issues with partner Glaxo Wellcome (NYSE:GLX - Quotes, News, Boards).
Zeffix sales surged to $20 million in the quarter, from $13.3 million just three months earlier.
Asian sales were especially strong. Further country approvals as well as reimbursement
should continue to fuel higher sales levels of Zeffix in future quarters.
Biochem achieved several key milestones in the first quarter that should drive shareholder
value over the course of this year. On March 15th, the company completed the divestiture of its
diagnostic business, a move that will enable it to focus resources on drug development
programs. Additionally, the company announced plans to partner with Technology
Partnerships Canada, a federal government agency, to develop protein vaccine technology.
The agreement provides for guaranteed funding to Biochem. Additionally, Biochem make
clinical progress on troxacitabine, an anti-cancer compound that the company is developing.
Biochem con
Titelgeschichte aus "Finanzen", Ausgabe März/April 2000
Dort werden 80 Biotechaktien im Test vorgestellt und eine ausführliche Rahmengeschichte mit Entwicklungsperspektiven der gesamten Branche.
Biochem Pharme: "HIV- und Hepatitis-Präperate auf dem Markt. Profitabel, gute Pipeline. Günstig bewertet. Basisanlage"
Damaliger Kurs: 24,28 C-Dollar
Umsatz in Mio:326,1 C-Dollar
Gewinn pro Aktie 2000: 1,47 C-Dollar
KGV: 16,6
MFG
Bandolin
Dort werden 80 Biotechaktien im Test vorgestellt und eine ausführliche Rahmengeschichte mit Entwicklungsperspektiven der gesamten Branche.
Biochem Pharme: "HIV- und Hepatitis-Präperate auf dem Markt. Profitabel, gute Pipeline. Günstig bewertet. Basisanlage"
Damaliger Kurs: 24,28 C-Dollar
Umsatz in Mio:326,1 C-Dollar
Gewinn pro Aktie 2000: 1,47 C-Dollar
KGV: 16,6
MFG
Bandolin
@ IWA japan
Sorry, natürlich auch durch deinen Thread.
Machts übrigens wieder gute, weil emotionsfreie Arbeit. Der Thread im Neuen Markt zu Vertex wird tatsächlich nur schwer zu "überbieten" sein. Es sei denn, du gehts zu Consors.
Übrigens: Wie siehst du die Entwicklung der nächsten Wochen bei CVTX?
MFG
bandolin
Sorry, natürlich auch durch deinen Thread.
Machts übrigens wieder gute, weil emotionsfreie Arbeit. Der Thread im Neuen Markt zu Vertex wird tatsächlich nur schwer zu "überbieten" sein. Es sei denn, du gehts zu Consors.
Übrigens: Wie siehst du die Entwicklung der nächsten Wochen bei CVTX?
MFG
bandolin
also nochmal kurz zu BCHE: spekuliere hier auch darauf, dass dieser bald im Bio Report auftauchen wird und die Leute sich um ihn reißen werden. Hordenbach sagte mal auf seiner Hotline, dass man damit sehr viel Geld verdienen kann in den nächsten Wochen.
Nichtsdestotrotz ist ja BCHE kein small-cap mehr eher ein konservativer Wert, was du ja an der Kursentwicklung siehst, aber dennoch ziemlich günstig, vor alem im Vergleich zu anderen Werten , bewertet.
Werde ihn jedenfalls weiter beobachten.
u CVTX: Ist einer meiner Favoriten bei den kleineren Werten unter 1 Mrd $ Marktwert.
Wollte ihn auch schon kaufen, habs aber verpasst. Warte jetzt erst mal ab.
Nichtsdestotrotz ist ja BCHE kein small-cap mehr eher ein konservativer Wert, was du ja an der Kursentwicklung siehst, aber dennoch ziemlich günstig, vor alem im Vergleich zu anderen Werten , bewertet.
Werde ihn jedenfalls weiter beobachten.
u CVTX: Ist einer meiner Favoriten bei den kleineren Werten unter 1 Mrd $ Marktwert.
Wollte ihn auch schon kaufen, habs aber verpasst. Warte jetzt erst mal ab.
Danke für die BO-Infos!
endlich ist es soweit. Bekam gerade eine email von BCHE bezüglich der Umsatzzahlen!!!!!
Habe ich vor ca. 24h fortgeschickt!!!
Habe ich vor ca. 24h fortgeschickt!!!
na ja, der große Reißer war es nicht, da sie aus irgend einem Grund keine Zalhen für die Zukunft nennen können. Aber nur so, die Anfrage wurde von deren IR-Abteilung innerhalb von nicht einmal von24h beantwortet, das ist doch was! (Achtung 19:23 unten ist die Kanada Zeit!) Aber lest selbst:
Hi Mr. IWA Japan,
I have included to tables with historical sales of Zeffiz and 3TC.
Unfortunately I cannot make any numerical projections for the market
potential but I will give you the following statistics:
Infectious diseases
- According to the World Health Organization, infectious diseases is the
cause of 25% of all deaths worldwide.
- It is expected to worsen due to the growth in population, increased
travel/ trade, environmental impacts on insect / animal populations and
resistance due to over use of antimicrobial agents.
3TC
- Growth in the HIV-treated market (Total number of people living with HIV
in the world = 33.6 million, newly infected people in 1999 = 5.6 million)
according to WHO.
- Unique benefits of M184V mutation. This mutated form of the HIV virus
that occurs in patients treated with 3TC is noticeably less fit than with
the wild-type HIV virus and does not replicate as fast. It has been
demonstrated that combination therapies which contain 3TC remain potent and
continue to suppress HIV even in the presence of 3TC resistant mutants.
- Role in new combination therapies. 3TC is used in Combivir (single tablet
conataining 3TC and AZT) and approval for Trizivir ( a triple combination)
is imminent.
- Introduction of Trizivir is expected in mid year 2000- Introduction of a once-day dosage is expected in 2001.
Somit dürfte das Wachstum in den Verkaufzahlen
gesichert sein, welches in letzter Zeit etwas mnach lies, wie von Claudia Barbiero mitgeteilt wurde:
Historical Sales of 3TC - including Combivir in US$ (Millions)
Canada USA Western Europe Rest of World Total Sales
Q1 2000 4,9 111,7 66,4 17,2 200,2
2000 4,9 111,7 66,4 17,2 200,2
Q4 1999 5,8 118,8 74,0 33,5 232,1
Q3 1999 5,4 111,4 65,9 20,8 203,5
Q2 1999 5,4 127,6 69,9 39,9 242,8
Q1 1999 4,5 101,3 69,2 19,7 194,7
1999 21,1 459,1 279,0 113,9 873,1
Q4 1998 5,2 114,9 70,0 34,5 224,6
Q3 1998 4,6 97,5 61,4 22,7 186,2
Q2 1998 5,3 103,0 65,0 39,3 212,6
Q1 1998 4,7 101,9 56,9 21,9 185,4
1998 19,8 417,3 253,3 118,4 808,8
Q4 1997 5,6 103,8 60,4 23,3 193,1
Q3 1997 5,1 101,1 50,3 22,3 178,8
Q2 1997 5,2 104,1 52,0 31,8 193,1
Q1 1997 4,6 83,5 39,0 10,9 138,0
1997 20,5 392,5 201,7 88,3 703,0
Q4 1996 4,3 83,1 28,8 10,5 126,7
Q3 1996 3,5 73,6 10,8 4,3 92,2
Q2 1996 3,2 51,3 0,5 0,2 55,2
Q1 1996 1,4 39,3 0,0 0,0 40,7
1996 12,4 247,3 40,1 15,0 314,8
nun wieder zurück zur Antwort:
Zeffix
- It is the only approved oral treatment for hepatitis B
- There are minimal side effects.
- Efficacy and durability of response
- It significantlyimproves liver function and hstology.
- It is approved on more than 50 countries and launched in about 30 of
those.
- Reimbusements are expected in key markets in 2000. It is already
reimbused in the US, Hong Kong, S. Korea and France.
- It is launched in most Asian markets where hepatitis is the most
prevalent.
- There is continued evidence of long-term clinical benefits.
- Increasing hepatitis B awareness and diagnosis
- No competition
Hier die bisherigen detaillierten Zahlen, welche deutliches Wachstum implizieren:
Historical Sales of Zeffix in US$ (Millions)
Canada USA Western Europe Rest of World Total Sales
Q1 2000 0,30 1,30 2,70 15,70 20,00
2000 0,30 1,30 2,70 15,70 20,00
Q4 1999 0,24 1,14 0,49 11,46 13,33
Q3 1999 0,19 0,39 0,97 6,35 7,90
Q2 1999 0,18 0,25 0,07 1,67 2,17
Q1 1999 0,10 0,51 n/a 0,20 0,81
1999 0,71 2,29 1,53 19,68 24,21
Q4 1998 0,11 2,60 n/a 0,13 2,84
1998 0,11 2,60 n/a 0,13 2,84
I invite you to visit our website at www.biochempharma.com where more
information is given on our products. Do not hesitate to contact me should
you require additional information. Please send your address should you want
some documents sent to you.
<<3TC Sales.xls>> <<Zeffix Sales.xls>>
Regards,
Claudia Barbiero
Investor Relations Assistant
BioChem Pharma
(450) 978-7755 (fax)
barbieroc@biochempharma.com
www.biochempharma.com
Weitere Umsätze werden ja noch durch Pacis und Fluviral ,siehe beides am THreadanfang, generiert
Bleibe im übrigen bei meiner Ansicht, dass in wenigen Wochen oder schlimmstenfalls Monaten die Bombe platzt und sich die Deutschen um diesen Wert reißen werden, da dieser dann im Biotech Report erscheint.Möglicher Titel: BCHE - Der AIDS-Knaller!
Übrigens heute BCHE wieder im Plus!
Noch was: Muss zugeben, dass ich momentan etwas Biochem-geil bin, dennoch glaube ich nach wie vor, dass BCHE doch mal was werden wird! Also weiter beobachten
Hi Mr. IWA Japan,
I have included to tables with historical sales of Zeffiz and 3TC.
Unfortunately I cannot make any numerical projections for the market
potential but I will give you the following statistics:
Infectious diseases
- According to the World Health Organization, infectious diseases is the
cause of 25% of all deaths worldwide.
- It is expected to worsen due to the growth in population, increased
travel/ trade, environmental impacts on insect / animal populations and
resistance due to over use of antimicrobial agents.
3TC
- Growth in the HIV-treated market (Total number of people living with HIV
in the world = 33.6 million, newly infected people in 1999 = 5.6 million)
according to WHO.
- Unique benefits of M184V mutation. This mutated form of the HIV virus
that occurs in patients treated with 3TC is noticeably less fit than with
the wild-type HIV virus and does not replicate as fast. It has been
demonstrated that combination therapies which contain 3TC remain potent and
continue to suppress HIV even in the presence of 3TC resistant mutants.
- Role in new combination therapies. 3TC is used in Combivir (single tablet
conataining 3TC and AZT) and approval for Trizivir ( a triple combination)
is imminent.
- Introduction of Trizivir is expected in mid year 2000- Introduction of a once-day dosage is expected in 2001.
Somit dürfte das Wachstum in den Verkaufzahlen
gesichert sein, welches in letzter Zeit etwas mnach lies, wie von Claudia Barbiero mitgeteilt wurde:
Historical Sales of 3TC - including Combivir in US$ (Millions)
Canada USA Western Europe Rest of World Total Sales
Q1 2000 4,9 111,7 66,4 17,2 200,2
2000 4,9 111,7 66,4 17,2 200,2
Q4 1999 5,8 118,8 74,0 33,5 232,1
Q3 1999 5,4 111,4 65,9 20,8 203,5
Q2 1999 5,4 127,6 69,9 39,9 242,8
Q1 1999 4,5 101,3 69,2 19,7 194,7
1999 21,1 459,1 279,0 113,9 873,1
Q4 1998 5,2 114,9 70,0 34,5 224,6
Q3 1998 4,6 97,5 61,4 22,7 186,2
Q2 1998 5,3 103,0 65,0 39,3 212,6
Q1 1998 4,7 101,9 56,9 21,9 185,4
1998 19,8 417,3 253,3 118,4 808,8
Q4 1997 5,6 103,8 60,4 23,3 193,1
Q3 1997 5,1 101,1 50,3 22,3 178,8
Q2 1997 5,2 104,1 52,0 31,8 193,1
Q1 1997 4,6 83,5 39,0 10,9 138,0
1997 20,5 392,5 201,7 88,3 703,0
Q4 1996 4,3 83,1 28,8 10,5 126,7
Q3 1996 3,5 73,6 10,8 4,3 92,2
Q2 1996 3,2 51,3 0,5 0,2 55,2
Q1 1996 1,4 39,3 0,0 0,0 40,7
1996 12,4 247,3 40,1 15,0 314,8
nun wieder zurück zur Antwort:
Zeffix
- It is the only approved oral treatment for hepatitis B
- There are minimal side effects.
- Efficacy and durability of response
- It significantlyimproves liver function and hstology.
- It is approved on more than 50 countries and launched in about 30 of
those.
- Reimbusements are expected in key markets in 2000. It is already
reimbused in the US, Hong Kong, S. Korea and France.
- It is launched in most Asian markets where hepatitis is the most
prevalent.
- There is continued evidence of long-term clinical benefits.
- Increasing hepatitis B awareness and diagnosis
- No competition
Hier die bisherigen detaillierten Zahlen, welche deutliches Wachstum implizieren:
Historical Sales of Zeffix in US$ (Millions)
Canada USA Western Europe Rest of World Total Sales
Q1 2000 0,30 1,30 2,70 15,70 20,00
2000 0,30 1,30 2,70 15,70 20,00
Q4 1999 0,24 1,14 0,49 11,46 13,33
Q3 1999 0,19 0,39 0,97 6,35 7,90
Q2 1999 0,18 0,25 0,07 1,67 2,17
Q1 1999 0,10 0,51 n/a 0,20 0,81
1999 0,71 2,29 1,53 19,68 24,21
Q4 1998 0,11 2,60 n/a 0,13 2,84
1998 0,11 2,60 n/a 0,13 2,84
I invite you to visit our website at www.biochempharma.com where more
information is given on our products. Do not hesitate to contact me should
you require additional information. Please send your address should you want
some documents sent to you.
<<3TC Sales.xls>> <<Zeffix Sales.xls>>
Regards,
Claudia Barbiero
Investor Relations Assistant
BioChem Pharma
(450) 978-7755 (fax)
barbieroc@biochempharma.com
www.biochempharma.com
Weitere Umsätze werden ja noch durch Pacis und Fluviral ,siehe beides am THreadanfang, generiert
Bleibe im übrigen bei meiner Ansicht, dass in wenigen Wochen oder schlimmstenfalls Monaten die Bombe platzt und sich die Deutschen um diesen Wert reißen werden, da dieser dann im Biotech Report erscheint.Möglicher Titel: BCHE - Der AIDS-Knaller!
Übrigens heute BCHE wieder im Plus!
Noch was: Muss zugeben, dass ich momentan etwas Biochem-geil bin, dennoch glaube ich nach wie vor, dass BCHE doch mal was werden wird! Also weiter beobachten
Tuesday June 27, 9:01 am Eastern Time
Press Release
SOURCE: Biochem Pharma Inc.
Biochem Pharma Sells its Stake in North American Vaccine
LAVAL, Quebec, June 27 /CNW/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; TSE: BCH - news) announced today that it has closed the transaction to sell to Baxter International, Inc. (NYSE: BAX - news; ``Baxter``) all of its shares of North American Vaccine, Inc. (AMEX: NVX - news; ``NAVA``).
For its NAVA shares, its debenture, the line of credit facility and the related interest and premium, BioChem Pharma is receiving total consideration of CAN$210 million. This consideration is composed of about 1.3 million Baxter shares and CAN$86 million.
``The divestment of our investment in NAVA is another milestone of our business plan. We believe it is an excellent outcome for our shareholders providing us with significant funds to redeploy in our product pipeline and our strategic initiatives,`` said Dr. Francesco Bellini, Chairman and Chief Executive Officer of BioChem Pharma.
BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human diseases with a focus in the anti-infective and anticancer areas.
BioChem Pharma news releases and other company information can be found on the World Wide Web at www.biochempharma.com.
Press Release
SOURCE: Biochem Pharma Inc.
Biochem Pharma Sells its Stake in North American Vaccine
LAVAL, Quebec, June 27 /CNW/ - BioChem Pharma Inc. (NASDAQ: BCHE - news; TSE: BCH - news) announced today that it has closed the transaction to sell to Baxter International, Inc. (NYSE: BAX - news; ``Baxter``) all of its shares of North American Vaccine, Inc. (AMEX: NVX - news; ``NAVA``).
For its NAVA shares, its debenture, the line of credit facility and the related interest and premium, BioChem Pharma is receiving total consideration of CAN$210 million. This consideration is composed of about 1.3 million Baxter shares and CAN$86 million.
``The divestment of our investment in NAVA is another milestone of our business plan. We believe it is an excellent outcome for our shareholders providing us with significant funds to redeploy in our product pipeline and our strategic initiatives,`` said Dr. Francesco Bellini, Chairman and Chief Executive Officer of BioChem Pharma.
BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human diseases with a focus in the anti-infective and anticancer areas.
BioChem Pharma news releases and other company information can be found on the World Wide Web at www.biochempharma.com.
6/29/00 Lehman Brothers BioChem Pharm initiated at Lehman Brothers with an Outperform Briefing.com
Credit Suisse First Boston reduziert BioChem Pharmaceuticals (BCHE) von STRONG BUY auf BUY. Unternehmen hat zwar einige vielversprechende Produkte in der Pipeline, bringt jedoch erst 2003 das nächste (Troxacitabine) auf den Markt. 8:33
Quelle=www.boerse-online.de
Quelle=www.boerse-online.de
BB Biotech hat seinen Anteil an BCHE deutlich reduziert (ich habe meinen auch schon lange auf NULL gefahren) , eine unendliche Geschichte, nur für Trader... Kanada Biotech läuft nicht !
ach was, BCHE ist eine Entdeckungsstory, was ich unten bereits sagte!ob die aus CAN oderUSA ist wurscht! oder besser worscht!
so ein Schmarn mit Kanada
die Amis kennen auch viele kanada WErte, s. Nortel und JDS Uniphase, sind zwar keine BT, aber dies gilt generell.
so ein Schmarn mit Kanada
die Amis kennen auch viele kanada WErte, s. Nortel und JDS Uniphase, sind zwar keine BT, aber dies gilt generell.
aktuell von Juchu.de
BioChem Pharma (BCHE) - wird ebenfalls am 26.07. seine Zahlen für das 2. Quartal präsentieren. Hier erwarten wir uns eine positive Überraschung. Experten erwarten sich bei 3TC einen Umsatz von 241 Millionen US$, bei ZEFFIX (ein Medikament zur Behandlung von Hepatitis B) einen Umsatz von 23 Millionen US$. Der Gewinn soll laut Analysten bei $ 0,23/Aktie liegen. Vor allem auf die Umsatzzahlen bei ZEFFIX sind wir sehr gespannt. Hier erwarten wir uns eine deutliche Steigerung gegenüber vorhergehenden Quartalen. BioChem hat erst kürzlich mit einem Abkommen mit Maxim Pharmaceuticals auf sich aufmerksam gemacht. Im Rahmen dieses Deals möchten die beiden Unternehmen ihre Forschungsarbeiten im Krebsbereich ausbauen. Wir glauben, dass bei BioChem längst nicht alle Perspektiven eingepreist sind und sehen unter mittel- bzw. langfristigen Gesichtspunkten ein schönes Kurspotential.
Bin ebenso gespannt
BioChem Pharma (BCHE) - wird ebenfalls am 26.07. seine Zahlen für das 2. Quartal präsentieren. Hier erwarten wir uns eine positive Überraschung. Experten erwarten sich bei 3TC einen Umsatz von 241 Millionen US$, bei ZEFFIX (ein Medikament zur Behandlung von Hepatitis B) einen Umsatz von 23 Millionen US$. Der Gewinn soll laut Analysten bei $ 0,23/Aktie liegen. Vor allem auf die Umsatzzahlen bei ZEFFIX sind wir sehr gespannt. Hier erwarten wir uns eine deutliche Steigerung gegenüber vorhergehenden Quartalen. BioChem hat erst kürzlich mit einem Abkommen mit Maxim Pharmaceuticals auf sich aufmerksam gemacht. Im Rahmen dieses Deals möchten die beiden Unternehmen ihre Forschungsarbeiten im Krebsbereich ausbauen. Wir glauben, dass bei BioChem längst nicht alle Perspektiven eingepreist sind und sehen unter mittel- bzw. langfristigen Gesichtspunkten ein schönes Kurspotential.
Bin ebenso gespannt
Ohhhhh CANADA
OT: PE ratio $11 great buy.
Core Earnings: Growth 24% year to date, 6% for qtr.
Core Earn/com share: 35% year to date, 14% for qtr.
Revenue Growth: 11% 6mth, 6% /qtr.
This cash cow has 48% return on assets, 68% return on equity, 102% Profit Margin, 54% Operating Margin with
How could you have a P/E ratio of 11 with above actual growth recorded and new drugs start just to market. Zeffix, PACIS just launched in US for bladder cancer, Phase II: BCH-3963 for pain, Troxatil for cancer.
OT: PE ratio $11 great buy.
Core Earnings: Growth 24% year to date, 6% for qtr.
Core Earn/com share: 35% year to date, 14% for qtr.
Revenue Growth: 11% 6mth, 6% /qtr.
This cash cow has 48% return on assets, 68% return on equity, 102% Profit Margin, 54% Operating Margin with
How could you have a P/E ratio of 11 with above actual growth recorded and new drugs start just to market. Zeffix, PACIS just launched in US for bladder cancer, Phase II: BCH-3963 for pain, Troxatil for cancer.
[
BioChem Pharma Inc., Posts 2Q EPS $1.59 vs. $0.33
BioChem Pharma Inc. Interim Consol. Earns. June `00-- Thou. Canadian Dollars
3 Mos. to June 30 2000 1999
Revenues 72,741 68,676
Net income 169,252 35,974
Share earns. (basic) $1.67 $0.33
Share earns. (diluted) $1.59 $0.33
6 Mos.:
Revenues 145,258 131,398
Inc. fr. Contng. opers. 209,681 66,180
Discontd. opers. -- (1,097)
Net income 209,681 65,083
Share earns. (basic)
Fr. contng. opers. $2.07 $0.61
Discontd. opers. -- (0.01)
Net income 2.07 0.60
Share earns. (diluted)
Fr. contng. opers. $1.99 $0.61
Discontd. opers. -- (0.01)
Net income 1.99 0.60
NEW YORK (Standard & Poor`s)--Jul 26, 2000, BioChem Pharma Inc., announced 2Q EPS $1.59 vs. $0.33 and 6 mos. EPS $1.99 vs. $0.61.
Results for 1999 exclude a loss of $0.01 per share for the 6 months from discontinued operations.
Email this story - View most popular stories emailed
BioChem Pharma Inc. Interim Consol. Earns. June `00-- Thou. Canadian Dollars
3 Mos. to June 30 2000 1999
Revenues 72,741 68,676
Net income 169,252 35,974
Share earns. (basic) $1.67 $0.33
Share earns. (diluted) $1.59 $0.33
6 Mos.:
Revenues 145,258 131,398
Inc. fr. Contng. opers. 209,681 66,180
Discontd. opers. -- (1,097)
Net income 209,681 65,083
Share earns. (basic)
Fr. contng. opers. $2.07 $0.61
Discontd. opers. -- (0.01)
Net income 2.07 0.60
Share earns. (diluted)
Fr. contng. opers. $1.99 $0.61
Discontd. opers. -- (0.01)
Net income 1.99 0.60
NEW YORK (Standard & Poor`s)--Jul 26, 2000, BioChem Pharma Inc., announced 2Q EPS $1.59 vs. $0.33 and 6 mos. EPS $1.99 vs. $0.61.
Results for 1999 exclude a loss of $0.01 per share for the 6 months from discontinued operations.
Email this story - View most popular stories emailed
BioChem in $3.8 mln deal
By Debra McGarry, CBS Marketwatch
Last Update: 6:11 PM ET Jul 28, 2000 NewsWatch
Latest headlines
LAVAL, QUEBEC (CBS.MW) -- BioChem Pharma announced Friday that it has agreed to acquire common shares of CliniChem Development from Glaxo Wellcome Inc. for $3.8 million in cash
BioChem (BCHE: news, msgs) will now own 20.6 percent of CliniChem common shares]
CliniChem was spun-off from BioChem in 1998 for the research and development of certain vaccine products for human use...[/b
The shares acquired from Glaxo represent approximately 14.6 percent of CliniChem shares.
The deal amounts to about $3.8 million, or $9.63 a share, in cash.
On January 10, BioChem said it planned to exercise its option to buyback all CliniChem shares when CliniChem`s funding ran out, which is expected by the end of the year.
Shares of the biopharmaceutical company closed off 3/8 at 22 1/16 while Glaxo (GLX: news, msgs) shares fell 1/8 to close at 58 1/2.
By Debra McGarry, CBS Marketwatch
Last Update: 6:11 PM ET Jul 28, 2000 NewsWatch
Latest headlines
LAVAL, QUEBEC (CBS.MW) -- BioChem Pharma announced Friday that it has agreed to acquire common shares of CliniChem Development from Glaxo Wellcome Inc. for $3.8 million in cash
BioChem (BCHE: news, msgs) will now own 20.6 percent of CliniChem common shares]
CliniChem was spun-off from BioChem in 1998 for the research and development of certain vaccine products for human use...[/b
The shares acquired from Glaxo represent approximately 14.6 percent of CliniChem shares.
The deal amounts to about $3.8 million, or $9.63 a share, in cash.
On January 10, BioChem said it planned to exercise its option to buyback all CliniChem shares when CliniChem`s funding ran out, which is expected by the end of the year.
Shares of the biopharmaceutical company closed off 3/8 at 22 1/16 while Glaxo (GLX: news, msgs) shares fell 1/8 to close at 58 1/2.
Research Analyst: Hal Levey (07/31/00)
Wednesday, Biochem Pharma (NASDAQ: BCHE - news) announced results for the second quarter of fiscal 2000 (all figures are in U.S. dollars, and per-share data uses an exchange rate of 1.4711). The company said earnings per share from continuing operations during the quarter, excluding one-time gains from the sale of its stake in North American Vaccine Inc., came to $0.26, above the analyst consensus estimate of $0.23 for the period. In the year-ago second quarter, Biochem`s earnings from continuing operations came to $0.22 per share.
Revenues grew 6% to $72.7 million in the latest quarter, from last year`s second quarter revenue tally of $68.7 million. The principal source of revenue comes from royalties on two products licensed by Biochem Pharma and sold by partner Glaxo Wellcome (NYSE: GLX - news): Zeffix, which treats chronic hepatitis B. Biochem Pharma said Wednesday that royalty revenues tied to these two drugs grew 4% in the second quarter, to $47.8 million.
Worldwide sales results of the two drugs were uneven. Biochem Pharma said second quarter sales of 3TC came to $219.8 million, a significant drop from the $242.8 million recorded a year earlier. The sales decline in the second quarter stems from what Biochem Pharma termed ``unusually higher`` sales in the prior year, which included non-recurring sales to Brazil. Analysts had been expecting higher sales results, around the low-to-mid $230 million mark,:O:O:O:O
for the drug,
Zeffix sales proved more gratifying, at $25 million in the quarter, a figure dominated by sales in the Far East, which accounted for about $20 million of that total. Sequential revenue growth in this product line has been strong. During the first quarter of fiscal 2000, Zeffix sales totaled $20 million. In the fourth quarter of 1999, sales were $13.3 million.
Besides its strong presence in Asia, Zeffix sales have also been growing at an impressive rate in other parts of the world. Looking at the latest quarter, in the U.S. Zeffix sales stood at around $1.7 million; last year that figure was around a quarter of a million dollars. Western Europe accounted for $2.8 million in Zeffix sales in the second quarter of fiscal year 2000. In the previous year sales to Western Europe amounted to a paltry $68,000. We expect to see higher sales levels for Zeffix in future quarters, especially in countries where Zeffix has recently been launched, including Greece, Spain and Italy. The company is also slated to launch Zeffix in Japan in November of this year, according to Prudential Securities analyst John Sonnier.
As we noted in an earlier update, Biochem Pharma has an attractive drug pipeline. Two agreements that trace their genesis to recent weeks look promising. Biochem has reached an in-licensing agreement with Cytovax Biotechnologies, which involves the development of a vaccine and possibly a therapeutic agent aimed at combating hospital-acquired infections. The second agreement, with Maxim Pharmaceuticals (NYSE: MAXM - news) was announced earlier this month and center on the development of a family of compounds that could help treat cancer.
In other pipeline developments, Biochem said the launch (outside Canada) of its first anti-cancer product, PACIS, is underway. Biochem says it aims to achieve a one-third market share of the world-wide bladder cancer market within five years.
In addition, the company has been steadily progressing through clinical trials for other offerings. Troxacitabine (for cancer) and BCH-3963 (for pain) are in phase II clinical trials. Two anti-HIV candidates are expected to enter phase I clinical trials next year. And phase I trials currently are underway for Biochem`s meningococcal vaccine and an influenza vaccine.
As we`ve noted before, shares of Biochem Pharma have been firmly entrenched in the low-to-mid $20 range. Shares barely budged on the news of a strong quarter marked by impressive Zeffix sales and a steadily-advancing drug pipeline. It may be the case that shares may have to wait for a lift via a ``catalyst`` - in this case, positive news from clinical trials during the second half. In any event, think the shares are still attractive at current levels and reiterate our ``buy`` recommendation on the stock.
Updated on 07/27/00 with BCHE at $23.25
Wednesday, Biochem Pharma (NASDAQ: BCHE - news) announced results for the second quarter of fiscal 2000 (all figures are in U.S. dollars, and per-share data uses an exchange rate of 1.4711). The company said earnings per share from continuing operations during the quarter, excluding one-time gains from the sale of its stake in North American Vaccine Inc., came to $0.26, above the analyst consensus estimate of $0.23 for the period. In the year-ago second quarter, Biochem`s earnings from continuing operations came to $0.22 per share.
Revenues grew 6% to $72.7 million in the latest quarter, from last year`s second quarter revenue tally of $68.7 million. The principal source of revenue comes from royalties on two products licensed by Biochem Pharma and sold by partner Glaxo Wellcome (NYSE: GLX - news): Zeffix, which treats chronic hepatitis B. Biochem Pharma said Wednesday that royalty revenues tied to these two drugs grew 4% in the second quarter, to $47.8 million.
Worldwide sales results of the two drugs were uneven. Biochem Pharma said second quarter sales of 3TC came to $219.8 million, a significant drop from the $242.8 million recorded a year earlier. The sales decline in the second quarter stems from what Biochem Pharma termed ``unusually higher`` sales in the prior year, which included non-recurring sales to Brazil. Analysts had been expecting higher sales results, around the low-to-mid $230 million mark,:O:O:O:O
for the drug, Zeffix sales proved more gratifying, at $25 million in the quarter
, a figure dominated by sales in the Far East, which accounted for about $20 million of that total. Sequential revenue growth in this product line has been strong. During the first quarter of fiscal 2000, Zeffix sales totaled $20 million. In the fourth quarter of 1999, sales were $13.3 million. Besides its strong presence in Asia, Zeffix sales have also been growing at an impressive rate in other parts of the world. Looking at the latest quarter, in the U.S. Zeffix sales stood at around $1.7 million; last year that figure was around a quarter of a million dollars. Western Europe accounted for $2.8 million in Zeffix sales in the second quarter of fiscal year 2000. In the previous year sales to Western Europe amounted to a paltry $68,000. We expect to see higher sales levels for Zeffix in future quarters, especially in countries where Zeffix has recently been launched, including Greece, Spain and Italy. The company is also slated to launch Zeffix in Japan in November of this year, according to Prudential Securities analyst John Sonnier.
As we noted in an earlier update, Biochem Pharma has an attractive drug pipeline. Two agreements that trace their genesis to recent weeks look promising. Biochem has reached an in-licensing agreement with Cytovax Biotechnologies, which involves the development of a vaccine and possibly a therapeutic agent aimed at combating hospital-acquired infections. The second agreement, with Maxim Pharmaceuticals (NYSE: MAXM - news) was announced earlier this month and center on the development of a family of compounds that could help treat cancer.
In other pipeline developments, Biochem said the launch (outside Canada) of its first anti-cancer product, PACIS, is underway. Biochem says it aims to achieve a one-third market share of the world-wide bladder cancer market within five years.
In addition, the company has been steadily progressing through clinical trials for other offerings. Troxacitabine (for cancer) and BCH-3963 (for pain) are in phase II clinical trials. Two anti-HIV candidates are expected to enter phase I clinical trials next year. And phase I trials currently are underway for Biochem`s meningococcal vaccine and an influenza vaccine.
As we`ve noted before, shares of Biochem Pharma have been firmly entrenched in the low-to-mid $20 range. Shares barely budged on the news of a strong quarter marked by impressive Zeffix sales and a steadily-advancing drug pipeline. It may be the case that shares may have to wait for a lift via a ``catalyst`` - in this case, positive news from clinical trials during the second half. In any event, think the shares are still attractive at current levels and reiterate our ``buy`` recommendation on the stock.
Updated on 07/27/00 with BCHE at $23.25
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
hier der 2 Jahreschart
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 217 | ||
| 90 | ||
| 77 | ||
| 60 | ||
| 50 | ||
| 36 | ||
| 34 | ||
| 31 | ||
| 27 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 19 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
